摘要
目的:探讨胃癌及其区域淋巴结CD44V6、nm23-H1表达与胃癌病理特征及预后的关系。方法:本研究采用SP免疫组织化学方法对110例胃癌及613枚区域淋巴结组织中的CD44V6、nm23-H1的表达进行检测。结果:在胃癌原发灶和在淋巴结转移灶,CD44V6阳性表达率分别为65.5%和89.4%,nm23-H1阳性表达率分别为39.1%和16.8%。CD44V6、nm23-H1表达率与胃癌的组织学类型、浸润深度、淋巴结转移密切相关。胃癌原发灶CD44V6阳性表达组5年生存率显著低于阴性表达组(P<0.01);nm23-H1阳性表达组5年生存率显著高于阴性表达组(P<0.01)。结论:对胃癌组织进行CD44V6、nm23-H1蛋白的检测,有助于预测胃癌进程和淋巴结转移的诊断,以及评估胃癌患者的预后。
Objective: To investigate the correlation between the expressions of CD44V6? nm23-H1 products in gastric carcinoma and regional lymph nodes with clinicopathologic features and prognosis of gastric cancer. Methods: The expressions of CD44V6? nm23-H1 in 110 advanced gastric carcinoma and 613 regional lymph node specimens were examined with immunohistochemical S-P technic. Results: The positive rate of CD44V6 was 65.5% and 89.4%, whereas the positive rate of nm23-H1 was 39.1% and 16.8% in primary gastric cancer and metastasis lymph nodes respectively. The positive rates of CD44V6? nm23-H1 were correlated with histological types? depth of invasion and node metastasis of gastric cancer.patients with CD44V6 positive regional lymph nodes had low 5-year survival rate (P<0.01), whereas patients with nm23-H1 positive regional lymph nodes had high 5-year survival rate (P<0.01). Conclusion: To detect CD44V6? nm23-H1 by immunohistochemistry would be useful in assessing tumor progression and lymphatic metastasis and in predicting prognosis of gastric cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2004年第5期256-258,共3页
Chinese Journal of Clinical Oncology
基金
河北省科技攻关计划项目资助(编号:97276160D)